NCT02555644View on ClinicalTrials.gov

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2016

Primary Completion Date

January 14, 2019

Study Completion Date

January 14, 2019

Conditions

Head and Neck Neoplasms

Interventions

DRUG

Prexasertib

Administered IV

DRUG

Cisplatin

Administered IV

DRUG

Cetuximab

Administered IV

RADIATION

Intensity Modulated Radiation Therapy

Trial Locations (4)

35249

University of Alabama at Birmingham Medical Center, Birmingham

69008

Centre Leon Berard, Lyon

77030

University of Texas MD Anderson Cancer Center, Houston

94805

Gustave Roussy, Villejuif

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT02555644 - A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer | Biotech Hunter | Biotech Hunter